. . "Coumarin derivative that acts as a long acting oral anticoagulant. [PubChem]"@en . . . "4-Hydroxy-3-(1-phenylpropyl)-2H-1-benzopyran-2-one"@en . . . . . "5-6 days"@en . . "Phenprocoumone"@en . . . . "3-(1'-Phenyl-propyl)-4-oxycoumarin"@en . "4-Hydroxy-3-(1-phenylpropyl)-2H-chromen-2-one"@en . . "50=500 mg/kg. Symptoms of overdose includes suspected or overt abnormal bleeding (e.g., appearance of blood in stools or urine, hematuria, excessive menstrual bleeding, melena, petechiae, excessive bruising or persistent oozing from superficial injuries)."@en . . . . "Phenprocumone"@en . . "Bioavailability is close to 100%"@en . . . . "Humans and other mammals"@en . . . "Used for the prevention and treatment of thromboembolic disease including venous thrombosis, thromboembolism, and pulmonary embolism as well as for the prevention of ischemic stroke in patients with atrial fibrillation (AF)."@en . . "approved"@en . . . "Phenprocoumonum"@en . . "Phenprocoumon inhibits vitamin K reductase, resulting in depletion of the reduced form of vitamin K (vitamin KH2). As vitamin K is a cofactor for the carboxylation of glutamate residues on the N-terminal regions of vitamin K-dependent proteins, this limits the gamma-carboxylation and subsequent activation of the vitamin K-dependent coagulant proteins. The synthesis of vitamin K-dependent coagulation factors II, VII, IX, and X and anticoagulant proteins C and S is inhibited. Depression of three of the four vitamin K-dependent coagulation factors (factors II, VII, and X) results in decreased prothrombin levels and a decrease in the amount of thrombin generated and bound to fibrin. This reduces the thrombogenicity of clots."@en . . " "@en . . "Phenprocoumarol"@en . "3-(alpha-Phenylpropyl)-4-hydroxycoumarin"@en . . . . . . "Phenprocoumarole"@en . . . . . . "3-(1-Phenylpropyl)-4-hydroxycoumarin"@en . "Fenprocumon"@en . . "Fenprocumone"@en . "99%"@en . "3-(alpha-Ethylbenzyl)-4-hydroxycoumarin"@en . "Phenprocoumon"@en . . "435-97-2"@en .